All In Biotech

Drug Trial Radar · NCT03070119

Long-Term Evaluation of BIIB067 (Tofersen)

An Extension Study to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB067 Administered to Previously Treated Adults With Amyotrophic Lateral Sclerosis Caused by Superoxide Dismutase 1 Mutation

Last checked: Nov 20, 2026Latest source record: Aug 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

139

Actual

Start

Mar 8, 2017

Primary completion

Aug 12, 2024

Study completion Aug 12, 2024

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
Collaborators
Ionis Pharmaceuticals, Inc.
First posted
Mar 3, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to evaluate the long-term safety and tolerability of BIIB067 (tofersen) in participants with amyotrophic lateral sclerosis (ALS) and confirmed superoxide dismutase 1 (SOD1) mutation. The secondary objectives are to evaluate the pharmacokinetic (PK), pharmacodynamic (PD), biomarker effects, and efficacy of BIIB067 administered to participants with ALS and a confirmed SOD1 mutation.

Conditions

  • ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation

Interventions

  • TofersenDrug

    Participants will receive a loading dose regimen followed by maintenance dosing.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious AEs (TESAEs)Time frame: From first dose of the study drug in the current study up to end of follow-up period (up to Week 364)

Locations

30 sites in 9 countries. Site status is shown where the registry gives one.

  • Research Site

    Phoenix, Arizona

  • Research Site

    La Jolla, California

  • Research Site

    San Francisco, California

  • Research Site

    Jacksonville, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Orlando, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Chicago, Illinois

  • Research Site

    Baltimore, Maryland

  • Research Site

    Boston, Massachusetts

  • Research Site

    Rochester, Minnesota

  • Research Site

    St Louis, Missouri

  • Research Site

    Lincoln, Nebraska

  • Research Site

    Cleveland, Ohio

  • Research Site

    Portland, Oregon

  • Research Site

    Knoxville, Tennessee

  • Research Site

    Leuven, Belgium

  • Research Site

    Calgary, Alberta, Canada

  • Research Site

    Edmonton, Alberta, Canada

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Montreal, Quebec, Canada

  • Bispebjerg Hospital

    Copenhagen, Denmark

  • Research Site

    Clermont-Ferrand, Puy De Dome, France

  • Research Site

    Ulm, Baden-Wurttemberg, Germany

  • Research Site

    Torino, Italy

  • Research Site

    Bunkyō City, Japan

  • Research Site

    Kagoshima, Japan

  • Research Site

    Shinjuku-ku, Japan

  • Research Site

    Suita-shi, Japan

  • Research Site

    Sheffield, South Yorkshire, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.